Kiniksa Pharmaceuticals Ltd (KNSA NASDAQ) stock market data APIs
$26.948
-0.42(-1.6%)
as of May 8, 2025
Kiniksa Pharmaceuticals Ltd Financial Data Overview
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Prev. Close
26.948
Open
26.5317
High
26.9345
Low
26.1965
52 wk Range
17.38-28.56
Market Cap
2 018 M
Shares Outstanding
42 336 K
Revenue
481 M
EPS
-0.12
Beta
0.311
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kiniksa Pharmaceuticals Ltd data using free add-ons & libraries
Get Kiniksa Pharmaceuticals Ltd Fundamental Data
Kiniksa Pharmaceuticals Ltd Fundamental data includes:
- Net Revenue: 481 M
- EBITDA: -14 228 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-25
- EPS/Forecast: 0.13
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kiniksa Pharmaceuticals Ltd News
New
3 Stocks Including Kiniksa Pharmaceuticals International That May Be Priced Below Intrinsic Value Estimates
The United States market has experienced a positive trajectory, climbing 2.7% in the last 7 days and showing a 9.6% increase over the past year, with earnings forecasted to grow by 14% annually. In su...
US High Growth Tech Stocks To Watch In April 2025
As the U.S. market faces a downturn with major indices like the S&P 500 and Nasdaq Composite experiencing declines following a weak GDP report, investors are closely monitoring economic indicators and...
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
– Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory dise...
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
Kiniksa Pharmaceuticals, Ltd. Hear from Carly about how she stepped into her own power. With the right diagnosis and support, she has been able to continue to pursue her successful career on stage. ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
